Skip to content

Ligand Pharmaceuticals LGND Convertible Preferred Stock Outstanding Shares

Convertible Preferred Stock Outstanding Shares at other companies

Revvity logo
RevvityRVTY
BridgeBio Pharma logo
BridgeBio PharmaBBIO
ALN
Alnylam PharmaceuticalsALNY
Halozyme Therapeutics logo
Halozyme TherapeuticsHALO
Incyte logo
IncyteINCY

Other financials

Income statement

See full
Revenue$51.7M+14.1%
Operating income$17.4M+148%
Net income-$13.3M+68.6%
EPS (diluted)-$0.67+69.7%

Balance sheet

See full
Cash & equivalents$115.1M+140%
Total debt$5.1M+14.2%
Total equity$997.3M+25.4%
Total assets$1.5B+69.2%

Cash flow

See full
Operating cash flow$48.7M+291%
CapEx$228.0K+6.5%
Free cash flow$48.5M+289%

Valuation

See full
Market cap$5.6B+96.7%

Profitability

See full
Gross margin91.9%
Operating margin34.5%+23.0pp
Net margin55.9%+35.7pp
FCF margin44.8%+16.8pp

Returns & leverage

See full
Return on equity17.1%+11.5pp
Debt / equity0.0×
Current ratio21.3×+16.0×

Where this comes from

Reported directly by Ligand Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockSharesOutstanding.

The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is Ligand Pharmaceuticals's convertible preferred stock outstanding shares?
Ligand Pharmaceuticals (LGND) reported convertible preferred stock outstanding shares of 0 in Q1 2026.